Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Algert Global LLC

Algert Global LLC cut its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 27.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 54,983 shares of the biopharmaceutical company’s stock after selling 20,631 shares during the period. Algert Global LLC owned approximately 0.08% of Celldex Therapeutics worth $1,869,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CLDX. KBC Group NV raised its stake in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Celldex Therapeutics during the 2nd quarter worth $76,000. CANADA LIFE ASSURANCE Co lifted its holdings in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares in the last quarter. Quest Partners LLC boosted its position in Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 6,879 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares in the last quarter.

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 3.80% of the stock is owned by corporate insiders.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $27.89 on Thursday. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.85 and a beta of 1.60. The stock’s fifty day moving average is $29.35 and its 200-day moving average is $34.60. Celldex Therapeutics, Inc. has a one year low of $22.93 and a one year high of $53.18.

Analyst Ratings Changes

Several analysts recently issued reports on CLDX shares. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research report on Monday, September 30th. They set a “neutral” rating and a $45.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.